The supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) continue to be limited, with supply not expected to return to normal until at least the end of 2024. The supply issues have been caused by an increase in demand for these products for licensed and off-label indications.

This National Patient Safety Alert provides further background and clinical information and actions for providers.

This NatPSA supersedes NatPSA/2023/008/DHSC.